3-(2,3-二氯苯基)-beta-丙氨酸 | 117391-56-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-(2,3-二氯苯基)-beta-丙氨酸
• 中文别名: (RS)-3-氨基-3-(2,3-二氯苯基)丙酸；(RS)-3-氨基-3-(2,3-二氯苯基)-丙酸
• 英文名称: 3-amino-3-(2,3-dichlorophenyl)propanoic acid
• 英文别名: 3-azaniumyl-3-(2,3-dichlorophenyl)propanoate
• CAS: 117391-56-7
• 化学式: C₉H₉Cl₂NO₂
• mdl: MFCD01871301
• 分子量: 234.082
• InChiKey: GQKLESLYMHWBOP-UHFFFAOYSA-N

物化性质

• 熔点：
  232-235

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  3-(2,3-二氯苯基)-beta-丙氨酸 在 N-甲基吗啉 、 氯化亚砜 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 (RS)-ethyl 3-(2,3-dichlorophenyl)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentanamido)propanoate
  参考文献：
  名称：

  Structure Activity Relationships of α_v Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents

  摘要：

  Antagonism of alpha(v)beta(6) is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an alpha(v)beta(3) antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved alpha(v)beta(6) activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan av antagonists having ca. 100 nM potency against alpha(v)beta(3), alpha(v)beta(5), alpha(v)beta(6), and av beta 8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC(50) values between the integrins in question) for alpha(v)beta(3) and alpha(v)beta(5).

  DOI：

  10.1021/ml5002079
• 作为产物：
  描述：

  丙二酸 、 2,3-二氯苯甲醛 在 乙酸铵 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 3-(2,3-二氯苯基)-beta-丙氨酸
  参考文献：
  名称：

  Rault, Sylvain; Dallemagne, Patrick; Robba, Max, Bulletin de la Societe Chimique de France, 1987, # 6, p. 1079 - 1083

  摘要：

  DOI：

文献信息

• SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF
  申请人：Brüggemeier Ulf

  公开号：US20100261771A1

  公开（公告）日：2010-10-14

  The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新的、取代的2-乙酰胺基-5-芳基-1,2,4-三唑酮，以及制备它们的方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。
• Novel β-Amino Acid Derivatives as Inhibitors of Cathepsin A
  作者：Sven Ruf、Christian Buning、Herman Schreuder、Georg Horstick、Wolfgang Linz、Thomas Olpp、Josef Pernerstorfer、Katrin Hiss、Katja Kroll、Aimo Kannt、Markus Kohlmann、Dominik Linz、Thomas Hübschle、Hartmut Rütten、Klaus Wirth、Thorsten Schmidt、Thorsten Sadowski

  DOI：10.1021/jm300663n

  日期：2012.9.13

  molecule inhibitors of CatA with oral bioavailability have been described to allow further pharmacological profiling. In our work we identified novel β-amino acid derivatives as inhibitors of CatA after a HTS analysis based on a project adapted fragment approach. The new inhibitors showed beneficial ADME and pharmacokinetic profiles, and their binding modes were established by X-ray crystallography. Further

  组织蛋白酶A（CatA）是分布在溶酶体，细胞膜和细胞外空间之间的丝氨酸羧肽酶。包括缓激肽和血管紧张素I在内的几种肽激素已被描述为底物。因此，抑制CatA在心血管疾病中具有有益作用的潜力。天然产物依贝内酯B对CatA的药理抑制作用可增加肾缓激肽水平，并防止盐诱导的高血压的发展。但是，到目前为止，尚未描述具有口服生物利用度的CatA小分子抑制剂可进行进一步的药理分析。在我们的工作中，基于基于项目的片段方法对HTS进行分析后，我们确定了新型β-氨基酸衍生物作为CatA抑制剂。新的抑制剂表现出有益的ADME和药代动力学特性，通过X射线晶体学建立了它们的结合方式。进一步的研究导致了迄今未知的CatA在心脏肥大中的病理生理作用。我们的一种抑制剂目前正在进行I期临床试验。
• 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto
  申请人：Yamamoto Yasuhito

  公开号：US20060178433A1

  公开（公告）日：2006-08-10

  The present invention is to provide an n-alkyl 3-amino-3-arylpropionate represented by the formula (I): wherein Ar 1 represents an aryl group which may have a substituent(s), provided that a phenyl group and 4-methoxyphenyl group are excluded, R 1 represents an n-propyl group or an n-butyl group, and a process for preparing the same, and its optically active compound and an optically active (S or R)-3-amino-3-arylpropionic acid represented by the formula (III-a): wherein Ar represents an aryl group which may have a substituent(s), and * represents an asymmetric carbon, and a process for preparing an optically active n-alkyl (R or S)-3-amino-3-arylpropionate represented by the formula (IV-a): wherein Ar and R 1 have the same meanings as defined above, * represents an asymmetric carbon, provided that it has a reverse absolute configuration to the compound of the formula (III-a).

  本发明提供了一种n-烷基3-氨基-3-芳基丙酸酯，其化学式表示为(I)：其中，Ar1表示一个芳基基团，可以具有一个或多个取代基，但不包括苯基和4-甲氧基苯基；R1表示一个n-丙基基团或n-丁基基团。本发明还提供了制备该化合物的方法，以及其光学活性化合物和光学活性(S或R)-3-氨基-3-芳基丙酸的化学式表示为(III-a)：其中，Ar表示一个芳基基团，可以具有一个或多个取代基，*表示一个不对称碳，以及制备光学活性n-烷基(R或S)-3-氨基-3-芳基丙酸酯的方法，其化学式表示为(IV-a)：其中，Ar和R1的含义与上述定义相同，*表示一个不对称碳，但其绝对构型与化合物的化学式(III-a)相反。
• Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08202895B2

  公开（公告）日：2012-06-19

  The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新的取代2-乙酰胺基-5-芳基-1,2,4-三唑酮，其制备过程，它们单独或联合用于治疗和/或预防疾病的用途，以及它们用于制造治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。
• 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO
  申请人：Ube Industries, Ltd.

  公开号：EP1621529A1

  公开（公告）日：2006-02-01

  The present invention is to provide an n-alkyl 3-amino-3-arylpropionate represented by the formula (I): wherein Ar1 represents an aryl group which may have a substituent(s), provided that a phenyl group and 4-methoxyphenyl group are excluded, R1 represents an n-propyl group or an n-butyl group, and a process for preparing the same, and its optically active compound and an optically active (S or R)-3-amino-3-arylpropionic acid represented by the formula (III-a): wherein Ar represents an aryl group which may have a substituent(s), and * represents an asymmetric carbon, and a process for preparing an optically active n-alkyl (R or S)-3-amino-3-arylpropionate represented by the formula (IV-a): wherein Ar and R1 have the same meanings as defined above, * represents an asymmetric carbon, provided that it has a reverse absolute configuration to the compound of the formula (III-a).

  本发明旨在提供一种由式（I）代表的 3-氨基-3-芳基丙酸正烷基酯： 其中 Ar1 代表芳基，该芳基可以具有取代基，但不包括苯基和 4-甲氧基苯基，R1 代表正丙基或正丁基、 及其光学活性化合物和由式（III-a）表示的光学活性（S 或 R）-3-氨基-3-芳基丙酸的制备方法： 其中 Ar 代表芳基，该芳基可能具有取代基，* 代表不对称碳、 以及一种制备由式（IV-a）代表的光学活性正烷基（R 或 S）-3-氨基-3-芳基丙酸酯的工艺： 其中 Ar 和 R1 的含义与上述定义相同，* 代表不对称碳，条件是其绝对构型与式 (III-a) 化合物相反。